Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma

被引:68
作者
Wallin, A
Sue-Chu, M
Bjermer, L
Ward, J
Sandström, T
Lindberg, A
Lundbäck, B
Djukanovic, R
Holgate, S
Wilson, S
机构
[1] Univ Umea Hosp, Dept Resp Med & Allergy, S-90185 Umea, Sweden
[2] Dept Lung Med, Trondheim, Norway
[3] Lund Univ, Dept Resp Med & Allergol, Lund, Sweden
[4] Univ Southampton, Sch Med, Dept Infect Inflammat & Repair, Southampton, Hants, England
[5] Boden Hosp, Dept Pulm Med, Boden, Sweden
[6] Karolinska Inst, Stockholm, Sweden
关键词
asthma; randomized controlled trial; bronchoscopy; fluticasone propionate; salmeterol; inflammation;
D O I
10.1067/mai.2003.1518
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: The clinical benefit of combining long-acting beta(2)-agonists with inhaled corticosteroids rather than doubling the dose of corticosteroid has been well-documented. However, there are concerns that this might result in a masking of underlying airway inflammation. Objective: The aim of this study was to test the hypothesis that the addition of the long-acting beta(2)-agonist salmeterol (SALM) to a low dose of the inhaled corticosteroid fluticasone propionate (FP) has a steroid-sparing effect and does not result in a worsening of bronchial inflammation compared to doubling the dose of inhaled corticosteroid. Methods: Fifty-six asthmatic subjects, previously not well-controlled on inhaled corticosteroids, were randomized to receive 3 months of treatment with inhaled FP 500 mug twice a day (FP 1000) or FP 200 mug twice a day plus SALM 50 mug twice a day (FP 400 + SALM). Fluticasone propionate 200 mug twice a day served as the control (FP400). Bronchial mucosal biopsy specimens, bronchial washings (BW), and bronchoalveolar lavage were obtained before and after treatment. The primary end points for the study were submucosal mast cell and eosinophil counts. Results: There was a significant improvement in FEV1 in the FP400 + SALM group compared to both the FP400 and FP1000 groups. This was accompanied by a significant improvement in peak expiratory flow in the FP400 + SALM group in both the morning and evening compared to the FP1000 group. There were no significant between treatment differences in the change in the number of submucosal mast cells or eosinophils. However, in the FP400 + SALM group there was a significant decrease in submucosal mast cells after 12 weeks of treatment. The addition of SALM to FP was not associated with any increases in airway inflammation in the biopsy specimens, bronchoalveolar lavage, or bronchial washings. Conclusion: These findings confirm that addition of SALM to FP has clinical benefits but does not mask or exacerbate airway inflammation and suggest that long-acting beta(2)-adrenoceptor agonists might influence mast cell numbers.
引用
收藏
页码:72 / 78
页数:7
相关论文
共 25 条
  • [1] ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91
  • [2] Adjusting for multiple testing when reporting research results: The Bonferroni vs Holm methods
    Aickin, M
    Gensler, H
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 1996, 86 (05) : 726 - 728
  • [3] Efficacy and safety of inhaled corticosteroids - New developments
    Barnes, PJ
    Pedersen, S
    Busse, WW
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (03) : S1 - S53
  • [4] Prednisolone treatment in asthma - Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa
    Bentley, AM
    Hamid, Q
    Robinson, DS
    Schotman, E
    Meng, Q
    Assoufi, B
    Kay, AB
    Durham, SR
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 153 (02) : 551 - 556
  • [5] IMMUNOHISTOCHEMISTRY ON RESIN SECTIONS - A COMPARISON OF RESIN EMBEDDING TECHNIQUES FOR SMALL MUCOSAL BIOPSIES
    BRITTEN, KM
    HOWARTH, PH
    ROCHE, WR
    [J]. BIOTECHNIC & HISTOCHEMISTRY, 1993, 68 (05) : 271 - 280
  • [6] Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study
    Brutsche, MH
    Brutsche, IC
    Munavvar, M
    Langley, SJ
    Masterson, CM
    Daley-Yates, PT
    Brown, R
    Custovic, A
    Woodcock, A
    [J]. LANCET, 2000, 356 (9229) : 556 - 561
  • [7] The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma
    Condemi, JJ
    Goldstein, S
    Kalberg, C
    Yancey, S
    Emmett, A
    Rickard, K
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1999, 82 (04) : 383 - 389
  • [8] EFFECT OF AN INHALED CORTICOSTEROID ON AIRWAY INFLAMMATION AND SYMPTOMS IN ASTHMA
    DJUKANOVIC, R
    WILSON, JW
    BRITTEN, KM
    WILSON, SJ
    WALLS, AF
    ROCHE, WR
    HOWARTH, PH
    HOLGATE, ST
    [J]. AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 145 (03): : 669 - 674
  • [9] Fluticasone propionate induced alterations to lung function and the immunopathology of asthma over time
    Faul, JL
    Leonard, CT
    Burke, CM
    Tormey, VJ
    Poulter, LW
    [J]. THORAX, 1998, 53 (09) : 753 - 761
  • [10] ADDED SALMETEROL VERSUS HIGHER-DOSE CORTICOSTEROID IN ASTHMA PATIENTS WITH SYMPTOMS ON EXISTING INHALED CORTICOSTEROID
    GREENING, AP
    IND, PW
    NORTHFIELD, M
    SHAW, G
    [J]. LANCET, 1994, 344 (8917) : 219 - 224